16 Noiembrie 2009
Antibiotices profit fell 7% in Q1-Q3
Local drug maker Antibiotice Iasi (ticker: ATB) said its profit fell 7% in the Jan-Sep period, to 15.7 million lei (€3.7 million), from the same period of last year.
In the first nine months of 2008, the company reported profit of 16.9 million lei and turnover of 155.4 million lei.
In 2009, the turnover increased slightly to 157.7 million lei (€37.3 million), while revenues fell 3.7% to 161.4 million lei (€38.2 million).
Expenses dropped 3.6% to 142.2 million lei (€33.7 million) compared to Jan-Sep period 2009.
In August, the drug maker said it would export products worth $2 million in US, after receiving license from the Food and Drug Administration.
The company has a share capital of 45.49 million lei, divided into 454.9 million shares at a face value of 0.10 lei.
The majority shareholder of the drug maker is the Ministry of Health with 53.01% interest, while FIC Oltenia holds 10.10%. Hyposwiss fund’s equity is below 5%, according to latest reports.
The company’s market cap is 304.7million lei (€70.9 million), according to yesterday’s closing quote of 0.67 lei/share.
In 2009, the turnover increased slightly to 157.7 million lei (€37.3 million), while revenues fell 3.7% to 161.4 million lei (€38.2 million).
Expenses dropped 3.6% to 142.2 million lei (€33.7 million) compared to Jan-Sep period 2009.
In August, the drug maker said it would export products worth $2 million in US, after receiving license from the Food and Drug Administration.
The company has a share capital of 45.49 million lei, divided into 454.9 million shares at a face value of 0.10 lei.
The majority shareholder of the drug maker is the Ministry of Health with 53.01% interest, while FIC Oltenia holds 10.10%. Hyposwiss fund’s equity is below 5%, according to latest reports.
The company’s market cap is 304.7million lei (€70.9 million), according to yesterday’s closing quote of 0.67 lei/share.